Synthetic opioids

Lyndra Therapeutics’ Investigational Oral, Weekly Opioid Use Disorder Treatment LYN-014 Granted Fast Track Designation by FDA

Retrieved on: 
Tuesday, July 27, 2021
Mental health, FDA, Health, Clinical trials, Pharmaceutical, Biotechnology, Drug rehabilitation, Drugs, Psychoactive drugs, Synthetic opioids, Ketones, Substance dependence, Medical specialties, Euphoriants, Methadone, Levomethadone, Opioid use disorder, Opioid, LYN-014, Opioid Use Disorder, Lyndra Therapeutics, LYN-014, OPIOID USE DISORDER, LYNDRA THERAPEUTICS

A weekly dosage form would free people from daily trips to methadone clinics and support consistency of treatment, recovery and wellbeing.

Key Points: 
  • A weekly dosage form would free people from daily trips to methadone clinics and support consistency of treatment, recovery and wellbeing.
  • The FDAs decision to grant LYN-014 Fast Track designation speaks to their commitment to provide people living with OUD with new, innovative treatment options.
  • LYN-014, which was granted investigational new drug status in April, is set to begin a Phase 1 clinical trial this quarter.
  • LYN-014, Lyndras investigational oral, ultra-long-acting extended-release weekly levomethadone capsule, is being developed for the treatment of people living with opioid use disorder (OUD).

Bereaved Parents Create Non-Profit to Combat Fentanyl Epidemic

Retrieved on: 
Sunday, July 18, 2021
Psychoactive drugs, Anilides, Piperidines, Synthetic opioids, Drugs, Chemical compounds, Designer drugs, Janssen Pharmaceutica, Fentanyl

Fentanyl, a cheap and powerful opioid, is the primary driver of the dramatic increase in drug deaths over the past year, according to the CDC .

Key Points: 
  • Fentanyl, a cheap and powerful opioid, is the primary driver of the dramatic increase in drug deaths over the past year, according to the CDC .
  • "Educating kids and families about the real dangers of fentanyl is just as important as monitoring platforms for drug activity.
  • In addition, Snap will also run a special episode of its award-winning news show, Good Luck America (GLA), devoted to the fentanyl epidemic and featuring an interview with Ed Ternan.
  • "We are honored to partner with Song for Charlie to educate young people on the dangers of counterfeit drugs and fentanyl poisoning.

New High Potency Synthetic Opioid Linked to Overdose Deaths Across United States

Retrieved on: 
Thursday, June 17, 2021
Psychoactive drugs, Drugs, Synthetic opioids, Analgesics, Anilides, Piperidines, General anesthetics, Janssen Pharmaceutica, Fentanyl, Opioid, Drug overdose, Etonitazene

WILLOW GROVE, Pa., June 17, 2021 /PRNewswire/ -- A novel synthetic opioid with purported potency greater than fentanyl has emerged in the United States and is linked to a growing number of overdose deaths across at least five states.

Key Points: 
  • WILLOW GROVE, Pa., June 17, 2021 /PRNewswire/ -- A novel synthetic opioid with purported potency greater than fentanyl has emerged in the United States and is linked to a growing number of overdose deaths across at least five states.
  • Dr. Barry Logan, Executive Director at the CFSRE, touted his laboratory's work with synthetic drugs and its growing collaborations with medical examiner and coroner offices across the United States.
  • N-Pyrrolidino etonitazene is a new high potency synthetic opioid which began appearing in the United States drug supply within the last month.
  • This increased potency means the drugs could present a high overdose risk for people using opioid drugs, and especially a high risk for those who use the drug unsuspectedly.

Fentanyl (CAS 437-38-7) Global Market Research Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 17, 2021
Health, Pharmaceutical, Drugs, Anilides, Piperidines, Synthetic opioids, Pharmacology, General anesthetics, Janssen Pharmaceutica, Fentanyl, Psychoactive drugs, Drug Enforcement Administration

The "Fentanyl (CAS 437-38-7) Global Market Research Report 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Fentanyl (CAS 437-38-7) Global Market Research Report 2021" report has been added to ResearchAndMarkets.com's offering.
  • This global report is a result of industry experts' diligent work on researching the world market of Fentanyl.
  • The fifth chapter deals with Fentanyl market trends and forecast, distinguish Fentanyl manufacturers and suppliers.
  • The Fentanyl global market report key points:

Lyndra Therapeutics Receives FDA Clearance of Investigational New Drug Application for LYN-014, its Once-Weekly Oral Levomethadone Treatment in Development for Opioid Use Disorder

Retrieved on: 
Thursday, May 6, 2021
Biotechnology, Mental health, Health, Pharmaceutical, Clinical trials, Drug rehabilitation, Drugs, Ketones, Synthetic opioids, Chemistry, Psychoactive drugs, Euphoriants, Nicotinic antagonists, Levomethadone, Methadone, Opioid use disorder, Opioid

b'Lyndra Therapeutics , a clinical-stage biotechnology company working to make daily pills a thing of the past, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for LYN-014, the Company\xe2\x80\x99s oral, ultra-long-acting, extended-release (ER) levomethadone capsule in development for the weekly treatment of opioid use disorder.

Key Points: 
  • b'Lyndra Therapeutics , a clinical-stage biotechnology company working to make daily pills a thing of the past, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for LYN-014, the Company\xe2\x80\x99s oral, ultra-long-acting, extended-release (ER) levomethadone capsule in development for the weekly treatment of opioid use disorder.
  • The IND clearance enables Lyndra to initiate a Phase 1 clinical trial in patients currently taking and controlled on daily oral immediate release (IR) methadone.
  • Levomethadone is an enantiomer of racemic methadone approved for use in Europe since the 1960s for pain management and opioid maintenance therapy.
  • Results from the 2016 National Survey on Drug Use and Health: Detailed Tables.

Opiant Pharmaceuticals Announces First Patient Dosed in Confirmatory Pharmacokinetic Study Assessing OPNT003, Nasal Nalmefene, for the Treatment of Opioid Overdose

Retrieved on: 
Monday, February 8, 2021
Opioids, Drugs, Psychoactive drugs, Medical emergencies, Morphinans, Opioid antagonists, Synthetic opioids, Tertiary alcohols, Fentanyl, Nalmefene, Drug overdose, Opioid epidemic in the United States

SANTA MONICA, Calif., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc.(Opiant) (NASDAQ: OPNT) today announced the dosing of the first patient in a confirmatory pharmacokinetic (PK) study for OPNT003, nasal nalmefene, for the treatment of opioid overdose.

Key Points: 
  • SANTA MONICA, Calif., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc.(Opiant) (NASDAQ: OPNT) today announced the dosing of the first patient in a confirmatory pharmacokinetic (PK) study for OPNT003, nasal nalmefene, for the treatment of opioid overdose.
  • Deaths resulting from opioid overdose are at record levels, driven in large part by high-potency synthetic opioids, such as fentanyl.
  • OPNT003 represents a potentially promising new approach for treating opioid overdoses, said Roger Crystal, M.D., CEO and President, Opiant.
  • OPNT003, nasal nalmefene, is in development as a potent, rapid-onset, long-acting opioid antagonist for the treatment of opioid overdose.

Nutriband Inc. Files Pro Forma Financials Consolidating the Recent Acquisition of Pocono Coated Products Transdermal and Topical Business and Active Intelligence

Retrieved on: 
Wednesday, January 13, 2021
Drugs, Analgesics, Organic compounds, Pain management, Euphoriants, Anilides, Piperidines, Synthetic opioids, Fentanyl, OTC Markets Group, Opioid epidemic in the United States, Opioid

ORLANDO, Fla., Jan. 13, 2021 /PRNewswire/ --Nutriband Inc. (OTCQB: NTRB), a Nevada Corporation, filed its form 8-K/A with the SEC for the audited financial reports of both Pocono Coated Products LLC and Active Intelligence and the combined pro forma financial statements with Nutriband Inc.

Key Points: 
  • ORLANDO, Fla., Jan. 13, 2021 /PRNewswire/ --Nutriband Inc. (OTCQB: NTRB), a Nevada Corporation, filed its form 8-K/A with the SEC for the audited financial reports of both Pocono Coated Products LLC and Active Intelligence and the combined pro forma financial statements with Nutriband Inc.
  • The Company is primarily engaged in the development of a portfolio of transdermal pharmaceutical products.
  • The product is combined with properties designed to help combat the opioid crisis by deterring the abuse and misuse of fentanyl patches.
  • Any material contained in or derived from any of the company's websites or any other website is not part of this press release.

Nutriband Inc. Records Record 375% Year-Over-Year Increase in Third Quarter Revenues and Record 69% Increase for Its Nine Month Revenues

Retrieved on: 
Wednesday, December 16, 2020
Drugs, Health care, Sackler family, Organic compounds, Analgesics, Anilides, Piperidines, Synthetic opioids, Opioid epidemic in the United States, Fentanyl, Opioid, Pharmaceutical industry in China

The increase in sales is attributed to the increase in ordersreceived byNutriband Inc.'swhollyowned subsidiary, Pocono Pharmaceuticals Inc., for its contract manufacturing services.

Key Points: 
  • The increase in sales is attributed to the increase in ordersreceived byNutriband Inc.'swhollyowned subsidiary, Pocono Pharmaceuticals Inc., for its contract manufacturing services.
  • The company expects sales to generally continue to increase in 2021.
  • The product is combined with properties designed to help combat the opioid crisis by deterring the abuse and misuse of fentanyl patches.
  • Any material contained in or derived from any of the company's websites or any other website is not part of this press release.

Nutriband Inc. Signs Exclusive License Agreement with RAMBAM Hospital Group for its Closed System Transfer Device

Retrieved on: 
Tuesday, December 15, 2020
Opioids, Drugs, Analgesics, Euphoriants, Anilides, Piperidines, Synthetic opioids, Fentanyl, CSTD, Rambam Health Care Campus, Opioid epidemic in the United States, Heroin

ORLANDO, Fla., Dec. 15, 2020 /PRNewswire/ --Nutriband Inc. (OTCQB: NTRB), a Nevada Corporation, announced that it signed an exclusive license agreement with RAMBAM Med Tech Ltd, a Division of the RAMBAM Hospital, the largest medical center in Northern Israel, for itsClosed System Transfer Device designed to liquify drugs for patients who cannot swallow solids.

Key Points: 
  • ORLANDO, Fla., Dec. 15, 2020 /PRNewswire/ --Nutriband Inc. (OTCQB: NTRB), a Nevada Corporation, announced that it signed an exclusive license agreement with RAMBAM Med Tech Ltd, a Division of the RAMBAM Hospital, the largest medical center in Northern Israel, for itsClosed System Transfer Device designed to liquify drugs for patients who cannot swallow solids.
  • The Closed System Transfer Device or CSTD combines the act of crushing a solid drug, dissolving in liquid and giving to a patient who cannot swallow for various reasons.
  • Following the signing of the exclusive license agreement with RAMBAM, the company plans to develop and file for 510K approval in the United States in the coming months.
  • The product is combined with properties designed to help combat the opioid crisis by deterring the abuse and misuse of fentanyl patches.

Study on Patented Non-Opioid MKO Melt® Reported in Leading Peer-Reviewed Anesthesia Journal

Retrieved on: 
Thursday, December 3, 2020
Medical specialties, Drugs, Clinical medicine, Anesthesia, General anesthetics, GABAA receptor positive allosteric modulators, Analgesics, Synthetic opioids, Fentanyl, Midazolam, Sedation

NASHVILLE, Tenn., Dec. 03, 2020 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) today announced that a study featuring its patented MKO Melt formulation has been published in the American Association of Nurse Anesthetists (AANA) Journal.

Key Points: 
  • NASHVILLE, Tenn., Dec. 03, 2020 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) today announced that a study featuring its patented MKO Melt formulation has been published in the American Association of Nurse Anesthetists (AANA) Journal.
  • The IRB-approved study compared the effectiveness and equivalency of a sublingual compounded non-opioid MKO Melt troche during monitored anesthesia sedation with traditional IV sedation for maintaining comfort in patients undergoing cataract surgery.
  • One group received IV sedation consisting of fentanyl and midazolam (n=54) and the other group received sublingual MKO Melt (n=53).
  • The authors of the study reported no financial relationships with any commercial related entity connected to the study.